Insider buying last 90 days
No open-market insider purchases were filed for ZYME in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ZYME insider filing, plotted on the chart in Gekko.Open ZYME in Gekko
NASDAQ: ZYME
Zymeworks (ZYME) Stock Analysis & Forecast
Oct 12 close
$25.33−0.46 (−1.8%)
Gekko Brief
AI summaryOct 12 closeZymeworks trades at $25.33, down 1.8%, sitting between its 50-day average of $26.56 and 200-day average of $25.08, a position that reflects a mixed short-term trend. The GekkoIndex reads 63.7, placing the stock in the Accumulation zone, up 2.7 over the past five readings. Price stands 21.5% below Gekko Fair Value of $32.28, a gap that has widened from the stock's 52-week range of $16.00 to $31.34.
Zymeworks reports next on 5 November 2026, 24 days away, falling inside a typical 20-trading-day holding window; its last report on 6 August showed an EPS of -0.62 against a -0.57 estimate with a 0.2% reaction, part of a record of 4 beats in the last 8 quarters and an average absolute move of 5% around results. No insider, Congress, or unusual options activity appears in the current windows, though one trailblazer holder is noted. Seasonally, the next 20 trading days have averaged a 9.4% move over 5 years, rising in 3 of them. All 12 covering analysts rate the stock a buy, with a consensus target of $41.21 implying 62.7% upside from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Zymeworks price vs fair value
Close $25.33200-day averageGekko Fair Value $32.28
Zymeworks quick facts
- Market cap
- $1.86B
- P/E ratio
- —
- Forward P/E
- 20.8
- EPS, TTM
- −$2.02
- Revenue, TTM
- $37.13M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.17
- Volume
- 2.34M avg 812,153
- 1-year return
- +49.7%
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±10.2%
- 50-day average
- $26.56
- 200-day average
- $25.08
- Next earnings
- Nov 5
- Shares outstanding
- 71.20M
Zymeworks swing-trade checklist
Zymeworks scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $25.33 sits between the 50-day ($26.56) and 200-day ($25.08) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.7, Accumulation
Reading 63.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
21.5% below
Price is 21.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+9.4% on average
From this point in the calendar, the next 20 trading days averaged +9.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Zymeworks stock chart and price history
Zymeworks closed at $25.33 on Oct 12, 2026, +49.7% over the past year, inside a 52-week range of $16.00 to $31.34.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −3.5%
- 3 months
- +2.7%
- 6 months
- −3.2%
- 1 year
- +49.7%
The full ZYME chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZYME in Gekko
Follow Zymeworks through every session
Put ZYME on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ZYME in GekkoFree for 7 days. No credit card required.
About Zymeworks
Zymeworks works on biological treatments for cancer that are still moving through clinical testing rather than already on the market. Among its programs are zanidatamab, a bispecific antibody being studied in Phase 1 and Phase 2 trials for cancers of the biliary tract, the gastroesophageal area, the breast and the colon, and ZW49, an antibody-drug conjugate aimed at two sites on HER2 that is in Phase 1 testing for tumors that express this protein and have spread or advanced.
The company pairs its research with partnerships rather than going it alone, working with larger pharmaceutical names such as Merck Sharp & Dohme, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Janssen Biotech, BeiGene and Exelixis. It also has research and licensing arrangements with LEO Pharma, focused on bispecific antibodies, and with Iconic Therapeutics.
Zymeworks was founded in 2003 and is headquartered in Vancouver, Canada. Its shares are listed on the NASDAQ under the ticker ZYME.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- zymeworks.com
Zymeworks GekkoIndex: the smart money zone
Zymeworks’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.7, in the Accumulation zone, up 2.7 points over five sessions.
63.7Accumulation
Up 2.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 15 | +6.2% | +6.7% | ||
| Accumulation (current zone) | 205 | +0.7% | +4.6% | ||
| Neutral | 410 | +0.8% | +2.9% | ||
| Distribution | 51 | +0.9% | +3.1% | ||
| Selling | 1 | Too few readings yet | |||
Average ZYME share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ZYME price, zone by zone.Track ZYME in Gekko
Is Zymeworks stock overvalued? Gekko Fair Value
Zymeworks trades 21.5% below Gekko Fair Value of $32.28, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zymeworks shares are worth, recalculated every trading day.
$32.28
Gekko Fair Value, Oct 10, 2026
21.5% Undervalued
At the end of Aug 2026 the price was 17.8% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ZYME in Gekko
Zymeworks insider and Congress trading
No open-market insider purchases were filed for Zymeworks, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ZYME were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ZYME, plotted on the chart in Gekko.Open ZYME in Gekko
Buybacks
Zymeworks has been buying back its own shares.
- Latest authorization
- $125.0M, Aug 6, 2026
- Bought back, quarter ended Jun 30, 2026
- $51.95M
- As a share of market cap
- 2.79%
- Trailing four quarters
- $169.6M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ZYME.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Zymeworks earnings: next date and track record
Zymeworks reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- $2.29
- Revenue estimate
- $227.4M
4 of 8reports beat the EPS estimate
±5%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.62 est −$0.57 | $4.59M est $4.54M | +0.2% |
| May 7, 2026 | −$0.59 est −$0.10 | — | −13.5% |
| Mar 2, 2026 | −$0.55 est −$0.35 | $2.52M est $19.24M | +5.0% |
| Nov 6, 2025 | −$0.26 est −$0.30 | $27.61M est $19.49M | −8.8% |
| Aug 7, 2025 | $0.03 est −$0.52 | $48.73M est $25.75M | −3.1% |
| May 8, 2025 | −$0.30 est −$0.45 | $27.11M est $18.02M | −0.3% |
| Mar 5, 2025 | −$0.31 est $0.01 | $31.03M est $15.20M | −4.9% |
| Oct 31, 2024 | −$0.39 est −$0.40 | $16.00M est $47.07M | −4.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Zymeworks stock forecast and analyst price targets
Analysts’ average 12-month price target for Zymeworks is $41.21, +62.7% from the last close, from 12 firms rating the stock in the last 90 days.
$41.21consensus 12-month target, +62.7% from the last close
Now $25.33Avg $41.21
Low $33High $55
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Truist Financial | $34 | +34.2% |
| Sep 29 | Citi | $39 | +54.0% |
| Sep 29 | Truist Financial | $32 | +26.3% |
| Sep 29 | Jefferies | $50 | +97.4% |
| Sep 29 | Evercore ISI | $44 | +73.7% |
+4.6%average 20-day move after past Accumulation readings
+9.4%average move over the next 20 trading days in the last 5 years
±4.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Zymeworks seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Zymeworks averaged +9.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.0% | 3 of 5 |
| Next 10 trading days | +0.6% | 3 of 5 |
| Next 15 trading days | +7.8% | 4 of 5 |
| Next 20 trading days | +9.4% | 3 of 5 |
| Next 30 trading days | +17.1% | 4 of 5 |
For scale, ZYME’s typical 20-trading-day move in either direction is about 10.2%.
Zymeworks market cap and key statistics
Zymeworks’s market cap is $1.86B and revenue of $37.13M over the last twelve months.
Valuation
- Market cap
- $1.86B
- Forward P/E
- 20.8
- EPS, TTM
- −$2.02
- Gekko Fair Value
- $32.28
Trading
- Volume
- 2.34M
- Avg volume, 20 days
- 812,153
- 52-week high
- $31.34
- 52-week low
- $16.00
- Shares outstanding
- 71.20M
Financials
- Revenue, TTM
- $37.13M
- Profit margin
- 0%
- Return on equity
- -72.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.17
- Typical daily move
- ±4.9%
- Typical 20-day move
- ±10.2%
Zymeworks peers
Zymeworks’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Zymeworks stock FAQ
What is Zymeworks’s market cap?
Zymeworks’s market cap is $1.86B at the Oct 12, 2026 close of $25.33, with 71.20M shares outstanding.
What is the Zymeworks stock forecast?
The consensus analyst 12-month price target for Zymeworks is $41.21, +62.7% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Zymeworks stock overvalued or undervalued?
On Gekko’s estimate Zymeworks is undervalued: the Oct 12, 2026 close of $25.33 is 21.5% below Gekko Fair Value of $32.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Zymeworks report earnings next?
Zymeworks is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of $2.29 per share on revenue of $227.4M. Zymeworks beat the earnings estimate in 4 of its last 8 reports, moving 5% on average across the report.
What is Zymeworks’s 52-week high and low?
Zymeworks’s 52-week high is $31.34 and its 52-week low is $16.00; it closed at $25.33 on Oct 12, 2026, +49.7% over the past year.
Is Zymeworks stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Zymeworks the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.